RxDoctor Payments Data

Cynthia Nortey, MD

Infectious Disease · Matthews, NCNPI 1629065644

Payments from drug & device makers

$1,070in general payments, 2019–2025

Across 51 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$338
  • Viiv Healthcare Company$220
  • Johnson & Johnson$184
  • Merck$138
  • AbbVie$74
  • Paratek Pharmaceuticals, Inc.$60
  • plus $56 from 2 others

What the payments were for

  • Food & beverage$1,070100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,070 in reported general payments places this provider in the 60th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$82,905
Medicare patients
260
Services billed
786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala104$464,707
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$236,700
GenvoyaElviteg/Cob/Emtri/Tenof Alafen35$145,963
OdefseyEmtricitab/Rilpiviri/Tenof Ala30$144,217
TriumeqAbacavir/Dolutegravir/Lamivudi32$120,362
TivicayDolutegravir Sodium23$80,208
JulucaDolutegravir/Rilpivirine18$65,187
Daptomycin20$50,474
ErtapenemErtapenem Sodium20$17,514
Vancomycin Hcl32$7,394
Cefepime Hcl21$3,923
Doxycycline Hyclate40$2,694
Cefazolin Sodium13$625
Cefdinir13$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$338$610,670139 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Juluca$220$265,75773 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →